Skip to content

Clinical trials

Observational Nasopharyngeal Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Nasopharyngeal Neoplasms Phase: Observational Clear all

32 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20021
20031
20051
20062
20073
20082
20101
20111
20132
20142
20151
20162
20172
20223
20232
20242
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Unknown status8
Recruiting6
Terminated3
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)4
M.D. Anderson Cancer Center3
Sun Yat-sen University3
Azienda Ospedaliero, Universitaria Pisana1
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1
King Saud University1
Konya Beyhekim Training and Research Hospital1
Memorial Sloan Kettering Cancer Center1
NYU Langone Health1
National Cancer Centre, Singapore1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Nasopharyngeal Neoplasms32
Oropharyngeal Neoplasms10
Head and Neck Neoplasms9
Laryngeal Neoplasms8
Mouth Neoplasms8
Hypopharyngeal Neoplasms7
Lung Neoplasms6
Esophageal Neoplasms5
Nasopharyngeal Carcinoma5
Salivary Gland Neoplasms5

Trials

Showing 76 to 32 of 32. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.